X4 PHARMACEUTICALS, INC Interest Expense
X4 PHARMACEUTICALS, INC (XFOR) reported Interest Expense of $2.41 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-11-13
- X4 PHARMACEUTICALS, INC interest expense for the quarter ending 2024-09-30 was $2.41M, a 47.74% increase year-over-year.
- X4 PHARMACEUTICALS, INC interest expense for the quarter ending 2024-06-30 was $2.18M, a 89.55% increase year-over-year.
- X4 PHARMACEUTICALS, INC interest expense for the quarter ending 2024-03-31 was $1.87M, a 68.98% increase year-over-year.
- X4 PHARMACEUTICALS, INC interest expense for the quarter ending 2023-12-31 was $1.89M, a 64.86% increase year-over-year.
- X4 PHARMACEUTICALS, INC interest expense for fiscal 2023 was $5.78M, a 44.68% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC interest expense for fiscal 2022 was $3.99M, a 9.64% increase from fiscal 2021.
- X4 PHARMACEUTICALS, INC interest expense for fiscal 2021 was $3.64M, a 35.49% increase from fiscal 2020.
- X4 PHARMACEUTICALS, INC interest expense for fiscal 2020 was $2.69M, a 25.20% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | $2.41M 10-Q · filed 2024-11-13 | $4.59M derived: sum of 2 quarters · filed 2024-11-13 | $6.46M 10-Q · filed 2024-11-13 | $8.35M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2024-06-30 | $2.18M 10-Q · filed 2024-08-08 | $4.05M 10-Q · filed 2024-08-08 | $5.94M derived: sum of 3 quarters · filed 2024-08-08 | $7.57M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2024-03-31 | $1.87M 10-Q · filed 2024-05-07 | $3.76M derived: sum of 2 quarters · filed 2024-05-07 | $5.39M derived: sum of 3 quarters · filed 2024-11-13 | $6.54M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $3.52M derived: sum of 2 quarters · filed 2024-11-13 | $4.67M derived: sum of 3 quarters · filed 2024-11-13 | $5.78M 10-K · filed 2024-03-21 | ||||
| 2023-09-30 | $1.63M 10-Q · filed 2024-11-13 | $2.78M derived: sum of 2 quarters · filed 2024-11-13 | $3.89M 10-Q · filed 2024-11-13 | $5.04M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $1.15M 10-Q · filed 2024-08-08 | $2.26M 10-Q · filed 2024-08-08 | $3.40M derived: sum of 3 quarters · filed 2024-08-08 | $4.42M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $1.11M 10-Q · filed 2024-05-07 | $2.25M derived: sum of 2 quarters · filed 2024-05-07 | $3.27M derived: sum of 3 quarters · filed 2024-05-07 | $4.19M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.16M derived: sum of 2 quarters · filed 2024-03-21 | $3.08M derived: sum of 3 quarters · filed 2024-03-21 | $3.99M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $1.02M 10-Q · filed 2023-11-09 | $1.94M derived: sum of 2 quarters · filed 2023-11-09 | $2.85M 10-Q · filed 2023-11-09 | $3.77M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-06-30 | $918.00K 10-Q · filed 2023-08-10 | $1.83M 10-Q · filed 2023-08-10 | $2.76M derived: sum of 3 quarters · filed 2024-03-21 | $3.68M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-03-31 | $913.00K 10-Q · filed 2023-05-04 | $1.84M derived: sum of 2 quarters · filed 2024-03-21 | $2.76M derived: sum of 3 quarters · filed 2024-03-21 | $3.66M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2021-12-31 | $925.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.84M derived: sum of 2 quarters · filed 2024-03-21 | $2.75M derived: sum of 3 quarters · filed 2024-03-21 | $3.64M 10-K · filed 2024-03-21 | ||||
| 2021-09-30 | $920.00K 10-Q · filed 2022-11-03 | $1.82M derived: sum of 2 quarters · filed 2022-11-03 | $2.72M 10-Q · filed 2022-11-03 | $3.44M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-06-30 | $905.00K 10-Q · filed 2022-08-04 | $1.80M 10-Q · filed 2022-08-04 | $2.52M derived: sum of 3 quarters · filed 2023-03-21 | $3.21M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-03-31 | $891.00K 10-Q · filed 2022-05-12 | $1.61M derived: sum of 2 quarters · filed 2023-03-21 | $2.31M derived: sum of 3 quarters · filed 2023-03-21 | $3.00M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2020-12-31 | $720.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $1.42M derived: sum of 2 quarters · filed 2023-03-21 | $2.10M derived: sum of 3 quarters · filed 2023-03-21 | $2.69M 10-K · filed 2023-03-21 | ||||
| 2020-09-30 | $697.00K 10-Q · filed 2021-11-04 | $1.38M derived: sum of 2 quarters · filed 2021-11-04 | $1.97M 10-Q · filed 2021-11-04 | $2.52M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-06-30 | $687.00K 10-Q · filed 2021-08-03 | $1.27M 10-Q · filed 2021-08-03 | $1.82M derived: sum of 3 quarters · filed 2022-03-17 | $2.51M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-03-31 | $584.00K 10-Q · filed 2021-05-06 | $1.13M derived: sum of 2 quarters · filed 2022-03-17 | $1.82M derived: sum of 3 quarters · filed 2022-03-17 | $2.33M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2019-12-31 | $548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.24M derived: sum of 2 quarters · filed 2022-03-17 | $1.75M derived: sum of 3 quarters · filed 2022-03-17 | $2.15M 10-K · filed 2022-03-17 | ||||
| 2019-09-30 | $688.00K 10-Q · filed 2020-11-05 | $1.20M derived: sum of 2 quarters · filed 2020-11-05 | $1.60M 10-Q · filed 2020-11-05 | $1.83M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-06-30 | $512.00K 10-Q · filed 2020-08-04 | $911.00K 10-Q · filed 2020-08-04 | $1.15M derived: sum of 3 quarters · filed 2021-03-19 | $1.29M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-03-31 | $399.00K 10-Q · filed 2020-05-07 | $635.00K derived: sum of 2 quarters · filed 2021-03-19 | $783.00K derived: sum of 3 quarters · filed 2021-03-19 | $950.00K derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2018-12-31 | $236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $384.00K derived: sum of 2 quarters · filed 2021-03-19 | $551.00K derived: sum of 3 quarters · filed 2021-03-19 | $720.00K 10-K · filed 2021-03-19 | $1.04M 10-K · filed 2019-03-11 | |||
| 2018-09-30 | $148.00K 10-Q · filed 2019-11-07 | $259.00K 10-Q · filed 2018-11-09 | $315.00K derived: sum of 2 quarters · filed 2019-11-07 | $484.00K 10-Q · filed 2019-11-07 | $785.00K 10-Q · filed 2018-11-09 | -$832.00K derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | $167.00K 10-Q · filed 2019-08-07 | $259.00K 10-Q · filed 2018-08-13 | $336.00K 10-Q · filed 2019-08-07 | $526.00K 10-Q · filed 2018-08-13 | -$980.00K derived: sum of 3 quarters · filed 2020-03-12 | -$637.00K derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | $169.00K 10-Q · filed 2019-05-15 | $267.00K 10-Q · filed 2018-05-10 | -$1.15M derived: sum of 2 quarters · filed 2020-03-12 | -$804.00K derived: sum of 3 quarters · filed 2020-03-12 | -$360.00K derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$973.00K derived: sum of 2 quarters · filed 2020-03-12 | -$529.00K derived: sum of 3 quarters · filed 2020-03-12 | $490.00K 10-K · filed 2020-03-12 | $2.08M 10-K · filed 2019-03-11 | |||
| 2017-09-30 | $343.00K 10-Q · filed 2018-11-09 | $787.00K derived: sum of 2 quarters · filed 2018-11-09 | $1.81M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | $444.00K 10-Q · filed 2018-08-13 | $1.46M 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | $1.02M 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | $2.52M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |